EMA Recommends Non-Renewal Of Authorisation Of Multiple Myeloma Medicine Blenrep; Recommendation Follows Review Of Available Data By CHMP As Part Of Renewal Of Blenrep's Marketing Authorisation
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency (EMA) has recommended the non-renewal of the authorisation of the multiple myeloma medicine Blenrep. This recommendation follows a review of available data by the Committee for Medicinal Products for Human Use (CHMP) as part of the renewal of Blenrep's marketing authorisation.
September 15, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The non-renewal recommendation for Blenrep by EMA could potentially impact GSK, the manufacturer of the drug, negatively in the short term.
Blenrep is a product of GSK. The non-renewal of its authorisation by EMA could lead to a decrease in sales and revenues for GSK, which could negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100